ProCE Banner Activity

FAQs: Optimizing Management of Patients with Triple-Negative Breast Cancer

Clinical Thought

In this commentary, expert faculty address frequently asked questions about the current optimal treatment of patients with triple-negative breast cancer.

Released: March 14, 2023

Expiration: March 12, 2024

No longer available for credit.

Share

Faculty

Mark Pegram

Mark Pegram

Professor
Medical Oncology
Stanford University
Palo Alto, California

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director
Clinical Trials, Breast Oncology
Director
Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Mark Pegram,

Professor
Medical Oncology
Stanford University
Palo Alto, California

Mark Pegram, MD: consultant/advisor/speaker: AstraZeneca/Daiichi Sankyo, Gilead, Roche/Genentech.

Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Director
Clinical Trials, Breast Oncology
Director
Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Sara Tolaney, MD, MPH: consultant/advisor: 4D Pharma, AstraZeneca, ARC Therapeutics, Athenex, BeyondSpring, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai Pharmaceuticals, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech/Roche, Gilead, Infinity Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana Therapeutics, Myovant, Novartis, Odonate, OncoSec Medical Incorporated, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zymeworks; steering committee: CytomX, Lilly, OncXerna; researcher (paid to institution): AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate, Pfizer, Sanofi, Seattle Genetics.